Large Independent Multi-Center Clinical Trial with Stratum Nutrition's NEM® Confirms Results in 7 Days
ncarol.com/10036789

CARTHAGE, Mo. - ncarol.com -- Stratum Nutrition®, the Global Leader of eggshell and eggshell membrane wellness ingredients, and President, Micah Osborne, announce, "NEM® has become an internationally recognized joint health ingredient as supported in a large, double-blind, placebo-controlled Clinical Trial from Turkey."

The Journal of Arthritis (J Arthritis 8(4):285.) recently published a large independent multi-center, randomized double-blind, placebo-controlled trial evaluating the efficacy of Stratum's flagship ingredient, NEM® brand eggshell membrane, in 166 subjects diagnosed with Grade 2 or Grade 3 osteoarthritis of the knee.

This study was conducted at eight different university medical centers in Turkey and confirmed NEM®'s fast results in only 7 days. By Day 30, both knee pain and stiffness had improved by more than 30% in the NEM® -treated subjects. This study also employed a unique blinded, single-crossover design to compare subjects taking NEM® for 90 days versus subjects taking NEM® for 60 days (the former placebo subjects who began taking NEM® after Day 30). A responder analysis found a statistically significant difference between the number of patients having at least a 15% decrease in pain, which was greater in the 90-day NEM® group (71% of subjects) compared to the 60-day NEM® group (53% of subjects).

More on ncarol.com

• Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
• New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
• Prince's Collaborator Shelby J To Be A Special Guest For "a Deadly Proposal" Red Carpet
• Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
• 7th Annual RACE INDUSTRY WEEK Returns Nov. 30 – Dec. 3 With Free Live Webinars From Racing Leaders

"This is the largest study conducted to date involving NEM® and we are pleased that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis. This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM® the perfect adjunctive therapy for those with joint issues," stated Kevin J. Ruff Ph.D., MBA – Sr. Director of Scientific & Regulatory Affairs for Stratum Nutrition.

For more information about Stratum Nutrition and its branded ingredients, please www.stratumnutrition.com.


About Stratum Nutrition

Stratum Nutrition^®, a business of ESM Technologies, LLC, sustainably provides world class nutrition ingredient solutions to nutritional product formulators for human and pet health. Stratum offers a portfolio of research-supported, branded ingredients that are progressive, safe and effective, including NEM^® brand eggshell membrane, ESC^® brand eggshell calcium, Ahiflower^® plant-based omegas-3,6,9, Curcumin 95, as well as oral-cavity probiotics, BLIS K12™ and BLIS M18™. These trusted ingredients are relied upon by consumers internationally. Visit www.stratumnutrition.com for more information.

More on ncarol.com

• Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
• IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
• AQUALIS of Morrisville, NC, Acquires Full Circle Environmental of Garner, NC
• FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
• Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA

NEM® & ESC® are trademarks of ESM Technologies, LLC, and are registered in the United States and other countries.

Ahiflower® is a registered trademark of Technology Crops International, LLC.

BLIS K12™ & BLIS M18™ are trademarks of Blis Technologies Limited and the subject of USA patent numbers 6773912 & 7226590.